Clinical Trials on Metabolic Dysfunction-associated Steatohepatitis (MASH) in South Africa

Total 57 results

Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis | MASH With Fibrosis

United States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NASH/MASH | NAFLD/MASLD

United States, Canada, Puerto Rico, Australia, India
Perspectum
King's College Hospital NHS Trust; University of Coimbra; Liverpool University... and other collaborators

Completed

Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1)

Metabolic Syndrome | NAFLD | NASH - Nonalcoholic Steatohepatitis

United Kingdom, Germany, Netherlands, Portugal
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
89bio, Inc.

Active, not recruiting

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (ENLIVEN)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
Boston Pharmaceuticals

Active, not recruiting

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Poxel SA

Completed

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NASH - Nonalcoholic Steatohepatitis

United States, Mexico, Puerto Rico
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Viking Therapeutics, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Mexico, Puerto Rico
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Non-alcoholic Steatohepatitis (NASH)

Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Madrigal Pharmaceuticals, Inc.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Spain, Australia, United Kingdom, Canada, Israel, Belgium, Italy, France, Puerto Rico, Switzerland, Germany, Austria, Poland, Mexico, Hungary
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
HighTide Biopharma Pty Ltd

Active, not recruiting

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes (CENTRICITY)

Type 2 Diabetes | Nonalcoholic Steatohepatitis (NASH)

United States, China, Hong Kong
Hepion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis (ASCEND)

NAFLD | Nonalcoholic Steatohepatitis (NASH) | Fibrosis, Liver

United States, France, Mexico
GlaxoSmithKline

Completed

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

Erectile Dysfunction

United States
Gilead Sciences

Terminated

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Liver Fibrosis Due to NASH

United States, Spain, France, Canada, Germany, Italy, Puerto Rico, United Kingdom, Belgium
Galectin Therapeutics Inc.

Active, not recruiting

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE)

Cirrhosis | NASH - Nonalcoholic Steatohepatitis | Prevention of Esophageal Varices

United States, France, Spain, Australia, Canada, Israel, Puerto Rico, Belgium, Argentina, Chile, Germany, Korea, Republic of, Mexico, Poland, United Kingdom
Bayer

Completed

Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia (LUTECIA)

Erectile Dysfunction

Israel, Italy, Colombia, Spain, Belgium, Finland, Mexico, Germany, South Africa, Netherlands, Norway, Peru, Sweden
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Gilead Sciences; Hoffmann-La... and other collaborators

Terminated

Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

HIV Infections | HIV-Associated Lipodystrophy

Australia
Pfizer

Completed

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Non-alcoholic Steatohepatitis

United States, Canada
Cogent Biosciences, Inc.

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Advanced Systemic Mastocytosis (AdvSM) | SM With an Associated Hematologic Neoplasm (SM-AHN) | Mast Cell Leukemia (MCL) | Aggressive Systemic Mastocytosis (ASM)

United States, Norway, Spain, Australia, Switzerland, Germany, Belgium, Netherlands, Canada, France, United Kingdom, Austria, Italy
Memory Pharmaceuticals

Unknown

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Cognitive Impairment Associated With Schizophrenia

United States
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Pfizer

Completed

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Macular Edema Associated With Diabetes Mellitus

United States, Colombia, Australia, Germany, Italy, South Africa, Greece, France, Austria, United Kingdom, Denmark, India, Portugal, Brazil, Canada, Czechia, Netherlands, Switzerland
Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Garvan Institute of Medical Research
National Health and Medical Research Council, Australia

Recruiting

Preventing Cognitive Decline With Metformin (MetMemory)

Cognitive Decline

Australia
Rhythm Pharmaceuticals, Inc.

Active, not recruiting

Long Term Extension Trial of Setmelanotide

Obesity Associated With Defects in Leptin-melanocortin Pathway

United States, Netherlands, Canada, Germany, United Kingdom, France, Greece, Spain
GlaxoSmithKline

Terminated

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (ELEVATE)

Liver Diseases | HIV Infection | Thrombocytopenia | Hepatitis C Virus | HBV | NASH - Nonalcoholic Steatohepatitis | Human Immunodeficiency Virus | Chronic Liver Disease | HCV | Non-alcoholic Steatohepatitis | Hepatitis B Virus

United States, Spain, Taiwan, Italy, Belgium, France, Korea, Republic of, Canada, Russian Federation, Pakistan, Poland, India, Argentina
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
Medical University of South Carolina

Recruiting

Cognitive Decline Following Deep Brain Stimulation

Parkinson Disease | Movement Disorders

United States
Medical University of South Carolina
Michael J. Fox Foundation for Parkinson's Research

Completed

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) (ATM-Cog)

Parkinson's Disease | Cognitive Impairment

United States
Biogen

Recruiting

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

United States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Alkahest, Inc.
Michael J. Fox Foundation for Parkinson's Research

Completed

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Parkinson Disease

United States, France, Australia

Clinical Trials on Metabolic Dysfunction-associated Steatohepatitis (MASH) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations